Relationships between Botulinum Toxin type, administer, and location with odds of adverse events
Findings from this cross-sectional study suggest that injectors operating from informal settings, particularly without disclosing the product used, pose a potential measurable and preventable risk. As public demand grows, safeguarding patient outcomes requires further legislative action.
Authors
- Dong Keon Yon (ORCID: https://orcid.org/0000-0003-1628-9948)
- Julia Gawronska (ORCID: https://orcid.org/0009-0008-1766-9719)
- Roshan Ravindran
- Lee Smith (ORCID: https://orcid.org/0000-0002-5340-9833)
- Damiano Pizzol (ORCID: https://orcid.org/0000-0003-4122-0774)
- Yvonne Barnett (ORCID: https://orcid.org/0000-0003-0271-2266)
- José Francisco López‐Gil (ORCID: https://orcid.org/0000-0002-7412-7624)
- Helen Keyes (ORCID: https://orcid.org/0000-0001-7654-3181)
- M Rahmati
- Laurent Boyer
- Laurie Butler
- Zena Salih
Institutions
- Ceres (US)
- WiLAN (Canada) (CA)
- Aix-Marseille Université (FR)
- Lorestan University (IR)
- Universidad Espíritu Santo (EC)
- Biruni University (TR)
- Kyung Hee University Medical Center (KR)
- National Directorate of Geology (MZ)
- Universidad de Los Lagos (CL)
- Ministry of Health (MZ)
- Anglia Ruskin University (GB)
Publication Details
- Journal
- Clinical and Experimental Dermatology
- Published
- 2026-03-14
- DOI
- https://doi.org/10.1093/ced/llag124
- Primary Topic
- Botulinum Toxin and Related Neurological Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00